New pill aims to slow vision loss in rare usher syndrome
NCT ID NCT04355689
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study tests whether NPI-001 tablets can safely slow or stop vision loss in people with Usher syndrome, a rare genetic condition that causes blindness and hearing loss. About 49 adults will take either the study drug or a placebo for 24 months. The main goal is to see if the drug helps preserve retinal sensitivity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CERA
Melbourne, Australia
-
Lions Eye Institute
Perth, Australia
-
Queensland Eye Institute
Brisbane, Australia
-
Sydney Eye Hospital / Save Sight Institute
Sydney, Australia